BioMarin PARP inhibitor advances in race with Tesaro drug
This article was originally published in Scrip
BioMarin Pharmaceutical will begin a Phase III clinical trial for its poly ADP-ribose polymerase (PARP) inhibitor BMN 673 in the treatment of breast cancer earlier than expected, keeping the company in a neck-and-neck race with its closest competitor Tesaro.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.